… EGFR tyrosine kinase inhibitors, gefitinib (Iressa), shows a highly specific affinity for EGFR
… EGFR and/or HER2 are highly expressed in many tumor types of epithelial origin, including …

… EGFR) tyrosine kinase inhibitor, gefitinib (Iressa), was approved in Japan and the United
States for the treatment … The original rationale for its use was the observation that EGFR is more …

… Toxicity profiles for the initial gefitinib and 2 nd EGFR-TKI treatments To determine whether
the initial gefitinib treatment and EGFR-TKI retreatment caused similar adverse events, we …

… the EGFR tyrosine kinase used for the targeted therapy of NSCLC patients in clinic. One is
gefitinib … signal even if EGFR activity is inhibited by gefitinib treatment.To test this hypothesis, …

… Based on the above findings, we suggest that sequencing of EGFR tyrosine kinase domain
… the customization of treatment using EGFR tyrosine kinase inhibitors as front-line treatment in …

… (EGFR; HER1) tyrosine kinase inhibitor (TKI) gefitinib, and more generally to EGFR TKIs, is
a … The availability of molecular criteria for predicting sensitivity to EGFR-TKIs is, therefore, the …

… 21 of the EGFR by gene sequencing. To understand the growth-inhibitory effects of gefitinib,
we investigated the effects of gefitinib treatment on cell cycle distribution and on EGFR and …

… target for therapy. However, small molecule inhibitors of the EGFR tyrosine kinase showed
… molecular effects of the tyrosine kinase inhibitor gefitinib on the EGFR signaling pathway in …

… to gefitinib in non–small-cell lung cancers containing EGFR … pretreatment resistance to
EGFR tyrosine kinase inhibitors. … role of EGFR mutations in the development of EGFR-related …

… Phosphorylation of the intracellular tyrosine kinase domain of EGFR enhances cell growth,
… Gefitinib is a selective EGFR-tyrosine kinase inhibitor that blocks the signal transduction …